These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1897287)

  • 1. [Systolic time intervals and echocardiography in monitoring adriamycin-treated tumor patients].
    Schott G
    Z Gesamte Inn Med; 1991 Jun; 46(8):280-2. PubMed ID: 1897287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring of heart function in the treatment with cardiotoxic cytostatic drugs].
    Richter von Arnauld HP; Kleeberg UR; Hassel C; Mergenthaler G; Erdmann H
    Onkologie; 1984 Feb; 7 Suppl 1():55-61. PubMed ID: 6371643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of Myocardial function during therapy with cardiotoxic cytostatics. Studies with the example of anthracycline-containing chemotherapy].
    Richter-v Arnauld HP; Kleeberg UR; Hassel C; Spehn J; Erdmann H
    Onkologie; 1982 Aug; 5(4):168-73. PubMed ID: 6755329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term study of anthracycline-induced cardiomyopathy in children and adolescents].
    Koch H; Schmitz L; Brockmeier K; Hartmann R; Bein G; Henze G
    Klin Padiatr; 1991; 203(4):262-7. PubMed ID: 1942932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits.
    Gersl V; Hrdina R
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1994; 37(2):49-55. PubMed ID: 7784798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters.
    Schmitt K; Tulzer G; Merl M; Aichhorn G; Grillenberger A; Wiesinger G; Hofstadler G
    Eur J Pediatr; 1995 Mar; 154(3):201-4. PubMed ID: 7758517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K
    Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Daunomycin-and adriamycin-induced cardiomyopathy--relationship between dosage of drugs and histopathological findings (author's transl)].
    Yamaguchi H; Toyota S; Takahara O; Ichimaru M
    Rinsho Ketsueki; 1978 Aug; 19(8):1041-50. PubMed ID: 713049
    [No Abstract]   [Full Text] [Related]  

  • 9. 1-year followup of cardiac status after adriamycin therapy.
    Friedman MJ; Ewy GA; Jones SE; Cruze D; Moon TE
    Cancer Treat Rep; 1979; 63(11-12):1809-16. PubMed ID: 526915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New methods in early diagnosis of a cardiomyopathy caused by adriamycin].
    Bühner R; Gottschalk R
    Onkologie; 1978 Dec; 1(6):258-62. PubMed ID: 153507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy].
    Göldel N; Autenrieth G; Werdan K; Knesewitsch P; Wilmanns W
    Z Kardiol; 1989 May; 78(5):320-7. PubMed ID: 2735093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.
    Suzuki J; Yanagisawa A; Shigeyama T; Tsubota J; Yasumura T; Shimoyama K; Ishikawa K
    Angiology; 1999 Jan; 50(1):37-45. PubMed ID: 9924887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis of adriamycin myocardiopathy using echocardiography].
    Harpf H; Lehnert M; Tschech G
    Acta Med Austriaca Suppl; 1979; 6():341-3. PubMed ID: 299226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular transmural systolic function by high-sensitivity velocity measurement "phased-tracking method" across the septum in doxorubicin cardiomyopathy.
    Koiwa Y; Kanai H; Hasegawa H; Saitoh Y; Shirato K
    Ultrasound Med Biol; 2002; 28(11-12):1395-403. PubMed ID: 12498934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin].
    Geidel S; Garn M; Grävinghoff L; Hausdorf G; Morf G; Bielack S; Knop J; Winkler K
    Klin Padiatr; 1991; 203(4):257-61. PubMed ID: 1942931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
    J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin cardiotoxicity. Prognostic value of the systolic time intervals.
    Chaudron JM; Beauduin M; Delwiche JP; Delannoy A; Luwaert R; Majois F; Lebacq EG; Pluygers E
    Acta Cardiol; 1982; 37(2):105-15. PubMed ID: 6980547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals.
    Villani F; Beretta G; Guindani A
    Cancer Chemother Pharmacol; 1979; 3(4):249-51. PubMed ID: 535135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive evaluation of anthracycline-induced cardiotoxicity in man.
    Lahtinen R; Uusitupa M; Kuikka J; Länsimies E
    Acta Med Scand; 1982; 212(4):201-6. PubMed ID: 7148515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.